28 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Conditions: Renal Cell Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Biological: Pazopanib;   Drug: Sunitinib;   Biological: Ipilimumab
2 Recruiting PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Interventions: Biological: Nivolumab;   Drug: Ipilimumab
3 Recruiting Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
4 Recruiting Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Erlotinib;   Biological: Ipilimumab
5 Not yet recruiting Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Condition: Kidney Cancer
Interventions: Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Ipilimumab
6 Not yet recruiting GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Condition: Previously Treated Metastatic Adenocarcinoma of the Pancreas
Interventions: Biological: CRS-207;   Biological: GVAX;   Drug: nivolumab;   Drug: CY
7 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
8 Recruiting A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Condition: CANCER,NOS
Interventions: Drug: Lirilumab;   Drug: Nivolumab
9 Recruiting A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
10 Recruiting A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
11 Recruiting A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer
Interventions: Drug: Ipilimumab;   Drug: Nivolumab
12 Recruiting A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
Condition: Recurrent Glioblastoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Bevacizumab
13 Recruiting An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Condition: Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
14 Recruiting Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
Condition: Advanced or Metastatic Melanoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
15 Recruiting A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Nivolumab
16 Recruiting Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)
Condition: Hodgkin Disease
Intervention: Drug: Nivolumab
17 Recruiting Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Condition: Lymphoma. Non-Hodgkin
Intervention: Drug: Nivolumab
18 Recruiting Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Nivolumab;   Drug: Cetuximab;   Drug: Methotrexate;   Drug: Docetaxel
19 Not yet recruiting Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Conditions: Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Sunitinib
20 Not yet recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: nivolumab;   Biological: ipilimumab;   Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment

Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results
Indicates status has not been verified in more than two years